Advanced Science | 单细胞+空间转录组定位 NSCLC 耐药生态位
Merged summary
TL;DR - A study combining single-cell and spatial transcriptomics identifies a therapy-resistant NSCLC niche where DSG2⁺ cancer stem cells co-localize with FAP⁺ myofibroblastic CAFs at tumor boundaries. The niche is associated with poorer chemotherapy, EGFR-TKI, and immunotherapy outcomes.
- A reproducible 127-gene cancer stem-cell signature identified DSG2 as its strongest marker.
- Spatial transcriptomics and multiplex immunofluorescence localized DSG2⁺ stem-like cells alongside FAP⁺ myCAFs at tumor borders.
- CellChat implicated MDK–NCL signaling, while co-culture experiments showed myCAFs enhance stemness through an MMP-dependent mechanism.
- DSG2 knockdown reduced stemness markers, self-renewal, invasion, and proliferation in NSCLC cell lines.
Sources (1)
Advanced Science | 单细胞+空间转录组定位 NSCLC 耐药生态位
TL;DR - A study combining single-cell and spatial transcriptomics identifies a therapy-resistant NSCLC niche where DSG2⁺ cancer stem cells co-localize with FAP⁺ myofibroblastic CAFs at tumor boundaries. The niche is associated with poorer chemotherapy, EGFR-TKI, and immunotherapy outcomes.
- A reproducible 127-gene cancer stem-cell signature identified DSG2 as its strongest marker.
- Spatial transcriptomics and multiplex immunofluorescence localized DSG2⁺ stem-like cells alongside FAP⁺ myCAFs at tumor borders.
- CellChat implicated MDK–NCL signaling, while co-culture experiments showed myCAFs enhance stemness through an MMP-dependent mechanism.
- DSG2 knockdown reduced stemness markers, self-renewal, invasion, and proliferation in NSCLC cell lines.